Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?
AbstractMetabolic changes during malignant transformation have been noted for many years in tumours. Otto Warburg first reported that cancer cells preferentially rely on glycolysis for energy production, even in the presence of oxygen, leading to the production of high levels of lactate. The crucial role of lactate efflux and exchange within the tumour microenvironment drew attention to monocarboxylate transporters (MCTs). MCTs have been recognized as promising targets in cancer therapy, and their expression was described in a large variety of tumours; however, studies showing how these isoforms contribute to the acquisition of the malignant phenotype are scarce and still unclear regarding prostate cancer. In this review, we focus on the role for MCTs in cell metabolism, supporting the development and progression of prostate cancer, and discuss the exploitation of the metabolic nature of prostate cancer for therapeutic and diagnostic purposes. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Pértega-Gomes, N.; Baltazar, F. Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know? Int. J. Mol. Sci. 2014, 15, 18333-18348.
Pértega-Gomes N, Baltazar F. Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know? International Journal of Molecular Sciences. 2014; 15(10):18333-18348.Chicago/Turabian Style
Pértega-Gomes, Nelma; Baltazar, Fátima. 2014. "Lactate Transporters in the Context of Prostate Cancer Metabolism: What Do We Know?" Int. J. Mol. Sci. 15, no. 10: 18333-18348.